EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Unveiling unique protein and phosphorylation signatures in lung adenocarcinomas with and without ALK , EGFR , and KRAS genetic alterations

Fanni Bugyi iD, Mirjam Balbisi, Simon Sugár, Lóránd Váncza, Eszter Regős, Ilona Kovalszky iD, Ibolya Laczó, Tünde Harkó, Gábor Kecskeméti, Zoltán Szabó iD, Judit Moldvay, László Drahos und 1 weitere

Molecular Oncology · 2025

DOI: 10.1002/1878-0261.70091 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Oncology, 2025. Verfasst von Fanni Bugyi und 12 weiteren Autor:innen. Beteiligte Einrichtung: MTA-HUN-REN TTK Lendület (Momentum) Glycan Biomarker Research Group, HUN-REN Research Centre for Natural Sciences, Budapest, Hungary. Hauptthemen laut MEDLINE: ErbB Receptors, Adenocarcinoma of Lung, Lung Neoplasms, Proto-Oncogene Proteins p21(ras). Die Arbeit nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Magyar Tudományos Akadémia, Nemzeti Kutatási, Fejlesztési és Innovaciós Alap.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Genetic alterations in key oncogenes have been frequently identified in lung adenocarcinoma (LUAD), including genes encoding epidermal growth factor receptor ( EGFR ), Kirsten rat sarcoma viral oncogene homolog ( KRAS ), and anaplastic lymphoma kinase ( ALK ). In this pilot study, we aimed to characterize the differences in enriched biological pathways and phosphorylation events between LUAD tumors harboring EGFR , KRAS , or echinoderm microtubule‐associated protein‐like 4 ( EML4 )– ALK oncogenic alterations and triple wild‐type LUAD tumors (WT, without EML4–ALK , KRAS , or EGFR alterations) by mass spectrometry (MS)‐based quantitative proteomics and phosphoproteomics. We analyzed tumor regions of 82 formalin‐fixed paraffin‐embedded (FFPE) tissue sections with 6, 23, 31, and 22 samples from the EML4–ALK , EGFR , KRAS , and WT sample groups, respectively. A total of 1377 to 2189 proteins and 73 to 1781 phosphosites were quantified in these analyses. Based on the results, the samples clustered according to their genetic alteration type, and EGFR ‐mutated samples showed unique protein expression patterns. Membrane organization, vesicle organization, and vesicle‐mediated transport Gene Ontology Biological Process (GOBP) terms were significantly downregulated in EGFR ‐mutated samples compared to the other sample groups. Changes in 36 proteins and 52 phosphosites were also identified as potentially specific to a given genetic alteration. Many of these proteins have previously been linked to EGFR or KRAS mutations [e.g., cathepsin L, stimulator of interferon genes protein (STING)], whereas several phosphoproteins are associated with RNA splicing [e.g., serine/arginine‐rich splicing factor 1 (SRSF1), SRSF2, and SRSF7 proteins]. Kinase–substrate enrichment analysis indicated altered activities of 10 kinases, including mitogen‐activated protein kinases (MAPKs) and cyclin‐dependent kinases (CDKs). For example, CDK2 activity was elevated in EML4–ALK samples compared to the other sample groups. Our results could provide significant insights into further studies that could contribute to developing improved diagnostic and therapeutic strategies for LUAD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ErbB ReceptorsAdenocarcinoma of LungLung NeoplasmsProto-Oncogene Proteins p21(ras)Anaplastic Lymphoma KinaseMutationHumansPhosphorylationProteomicsFemaleMaleAgedOncogene Proteins, FusionMiddle Aged

Stichwörter der Autor:innen

FFPE tissuecancer researchgenetic alterationslung adenocarcinomamass spectrometryphosphoproteomics

Substanzen

ErbB ReceptorsProto-Oncogene Proteins p21(ras)KRAS protein, humanAnaplastic Lymphoma KinaseEGFR protein, humanALK protein, humanOncogene Proteins, Fusion

Autor:innen und Institutionen

  • MTA-HUN-REN TTK Lendület (Momentum) Glycan Biomarker Research Group, HUN-REN Research Centre for Natural Sciences, Budapest, Hungary.
  • Hevesy György PhD School of Chemistry, ELTE Eötvös Loránd University, Budapest, Hungary.
  • Semmelweis University Doctoral School, Budapest, Hungary.
  • Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
  • Békés County Central Hospital, Gyula, Hungary.
  • National Korányi Institute of Pulmonology, Budapest, Hungary.

ORCID-Profile: Fanni Bugyi, Ilona Kovalszky, Zoltán Szabó, Lilla Turiák

Förderung

  • Magyar Tudományos Akadémia
  • Nemzeti Kutatási, Fejlesztési és Innovaciós Alap

Zitieren

APA

Bugyi, F., Balbisi, M., Sugár, S., Váncza, L., Regős, E., Kovalszky, I., Laczó, I., Harkó, T., Kecskeméti, G., Szabó, Z., Moldvay, J., Drahos, L., & Turiák, L. (2025). Unveiling unique protein and phosphorylation signatures in lung adenocarcinomas with and without ALK , EGFR , and KRAS genetic alterations. Molecular Oncology. https://doi.org/10.1002/1878-0261.70091

Vancouver

Bugyi F, Balbisi M, Sugár S, Váncza L, Regős E, Kovalszky I, et al. Unveiling unique protein and phosphorylation signatures in lung adenocarcinomas with and without ALK , EGFR , and KRAS genetic alterations. Molecular Oncology. 2025. doi:10.1002/1878-0261.70091

BibTeX
@article{Bugyi2025,
  author = {Bugyi, Fanni and Balbisi, Mirjam and Sugár, Simon and Váncza, Lóránd and Regős, Eszter and Kovalszky, Ilona and Laczó, Ibolya and Harkó, Tünde and Kecskeméti, Gábor and Szabó, Zoltán and Moldvay, Judit and Drahos, László and Turiák, Lilla},
  title = {Unveiling unique protein and phosphorylation signatures in lung adenocarcinomas with and without ALK , EGFR , and KRAS genetic alterations},
  journal = {Molecular Oncology},
  year = {2025},
  doi = {10.1002/1878-0261.70091}
}
Kostenlos starten →